BANF family member 2Genealiases: BAF-L · BAF2 · BAFL · C20orf179
Q-omics provides the consensus-scored BANF2 profile across patient tissues and cancer cell-line models. BANF2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, BANF2 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, BANF2 RNA expression shows 7,016 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LGG, THCA, and STAD as cancer lineages where BANF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BANF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BANF2 survival associations across molecular data types. BANF2 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BANF2 RNA expression–survival associations across cancer types. High BANF2 expression shows unfavorable associations in LGG, HNSC, PAAD, ACC and THYM, but favorable associations in BRCA. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for BANF2 RNA expression.
This table summarizes BANF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for BANF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BANF2 shows lower tumor expression in THCA, BRCA, KICH and UCEC and higher tumor expression in LIHC and LUAD. The THCA box plot shows higher BANF2 RNA expression in normal versus tumor tissue (log2 FC = −1.238, t-test p < 0.001).
This table shows molecular features associated with BANF2 in patient tissues and cancer cell lines. In patient samples, BANF2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, BANF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LUNG_NSCLC_LUAD.
